Related Experiment Videos
A clinical trial of nafazatrom (Bay g 6575) in advanced cancer
Abstract:
Nafazatrom (Bay g 6575) has been shown to be a potent inhibitor of tumor metastasis in preclinical models. It is believed to work by stimulating endogenous prostacyclin production. The drug has also been shown to inhibit the growth of certain experimental tumors, to be cytostatic for certain cell lines in tissue culture, and to induce differentiation in HL-60, neuroblastoma, and Friend erythroleukemia cell lines. Furthermore, no toxicity has been seen in animals or human volunteers. We report here a clinical trial of oral nafazatrom at five dose levels in patients with advanced cancer. Thirty patients with a wide variety of advanced malignancies were treated for 26-638+ days (median 82 days). No tumor responses were seen. Toxicity included two cases with mild skin rashes, one case with nausea and vomiting, and one case with diarrhea. Nafazatrom is a safe and well-tolerated agent. Maximum activity would be predicted to occur in the adjuvant treatment of cancer and we feel that further efforts should proceed to identify the appropriate dose for such a trial.
Insights
Nafazatrom, a drug that stimulates prostacyclin, showed no tumor response in advanced cancer patients. However, it proved safe and well-tolerated, suggesting potential for adjuvant cancer therapy.
Area of Science:
- Oncology
- Pharmacology
Background:
- Nafazatrom inhibits tumor metastasis in preclinical models.
- It stimulates endogenous prostacyclin production.
- Nafazatrom exhibits anti-tumor properties, including cytostatic effects and differentiation induction in cell lines.
Purpose of the Study:
- To evaluate the safety and efficacy of oral nafazatrom in patients with advanced cancer.
- To determine the maximum tolerated dose and preliminary activity of nafazatrom.
Main Methods:
- A clinical trial was conducted with thirty patients diagnosed with advanced malignancies.
- Patients received oral nafazatrom at five different dose levels.
- Treatment duration varied, with a median of 82 days.
Main Results:
- No tumor responses were observed in any of the patients treated.
- Nafazatrom was found to be safe and well-tolerated.
- Adverse events were mild, including skin rashes, nausea, vomiting, and diarrhea.
Conclusions:
- Nafazatrom is a safe and well-tolerated agent in patients with advanced cancer.
- Further investigation is warranted to explore its potential in adjuvant cancer treatment.
- Identifying the optimal dose for adjuvant therapy is recommended.